BlackRock’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-54,721
Closed -$138K 5250
2020
Q2
$138K Sell
54,721
-15,078
-22% -$28.6K ﹤0.01% 4439
2020
Q1
$89K Buy
69,799
+11,757
+20% +$24K ﹤0.01% 4369
2019
Q4
$163K Sell
58,042
-3,737
-6% -$12K ﹤0.01% 4357
2019
Q3
$328K Sell
61,779
-1,590
-3% -$10.6K ﹤0.01% 4245
2019
Q2
$608K Sell
63,369
-123,541
-66% -$2.27M ﹤0.01% 4146
2019
Q1
$5.01M Sell
186,910
-4,609
-2% -$117K ﹤0.01% 3412
2018
Q4
$4.33M Sell
191,519
-24,294
-11% -$950K ﹤0.01% 3438
2018
Q3
$11.9M Buy
215,813
+7,197
+3% +$460K ﹤0.01% 3146
2018
Q2
$14.9M Buy
208,616
+7,494
+4% +$529K ﹤0.01% 3030
2018
Q1
$12.3M Sell
201,122
-1,095
-0.5% -$96.1K ﹤0.01% 3021
2017
Q4
$25.5M Buy
202,217
+35,365
+21% +$4.53M ﹤0.01% 2659
2017
Q3
$22.8M Buy
166,852
+48,425
+41% +$6.48M ﹤0.01% 2732
2017
Q2
$16.9M Buy
118,427
+3,392
+3% +$524K ﹤0.01% 2885
2017
Q1
$21.1M Buy
115,035
+114,654
+30,093% +$12.9M ﹤0.01% 2724
2016
Q4
$30K Sell
381
-32
-8% -$2.53K ﹤0.01% 3138
2016
Q3
$32K Hold
413
﹤0.01% 3149
2016
Q2
$35K Buy
413
+287
+228% +$26.3K ﹤0.01% 3087
2016
Q1
$12K Sell
126
-40
-24% -$4K ﹤0.01% 3092
2015
Q4
$33K Buy
166
+88
+113% +$17.6K ﹤0.01% 2304
2015
Q3
$12K Buy
78
+24
+44% +$17.6K ﹤0.01% 2658
2015
Q2
$51K Buy
54
+20
+59% +$16.4K ﹤0.01% 1975
2015
Q1
$25K Buy
34
+5
+17% +$3.76K ﹤0.01% 2256
2014
Q4
$23K Hold
29
﹤0.01% 2307
2014
Q3
$12K Hold
29
﹤0.01% 2628
2014
Q2
$8K Buy
29
+3
+12% +$644 ﹤0.01% 2955
2014
Q1
$6K Buy
26
+7
+37% +$1.95K ﹤0.01% 3025
2013
Q4
$5K Buy
+19
New +$4.53K ﹤0.01% 3058

BlackRock's TTPH Position: Q3 2020 in Review

BlackRock sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2020, closing a stake of 54,721 shares — an estimated $138K sold.

BlackRock first reported a position in TTPH in Q4 2013 and held it in 27 quarters. The position peaked at $25.5M in Q4 2017. 1 fund tracked by Wall St. Rank holds TTPH as of Q3 2020.

  • BlackRock reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • BlackRock sold 54,721 Tetraphase Pharmaceuticals, Inc. shares in Q3 2020, an estimated $138K.
  • BlackRock first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2013 and held it in 27 quarters.
  • BlackRock's Tetraphase Pharmaceuticals, Inc. position peaked at $25.5M in Q4 2017.
  • 1 fund tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2020.

Based on BlackRock's 13F filing for Q3 2020, filed 6 Nov 2020.